Shanghai Shiling Pharmaceutical

Shanghai Shiling Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative small molecule drugs for oncology and autoimmune disorders. The company's research strategy focuses on optimizing kinase inhibitors to achieve superior selectivity and reduced toxicity compared to first-generation therapies. Its lead candidate, SL-001, is a potent CDK4/6 inhibitor currently undergoing clinical evaluation for the treatment of advanced breast cancer and other solid tumors. Additionally, the company is advancing SL-002, a PI3K inhibitor, through early-stage clinical trials. Shanghai Shiling Pharmaceutical aims to address unmet medical needs by delivering high-quality, differentiated therapeutic options to patients globally.